Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Ivabradine Stories

2014-04-14 12:31:23

Considerable Opportunity Exists for Therapies Offering Reductions in Mortality and Hospitalization Rates, According to Findings from Decision Resources Group BURLINGTON, Mass., April 14, 2014 /PRNewswire/ -- Decision Resources Group finds that Servier's ivabradine (procoralan) is set to become the clinical gold-standard in the treatment of chronic heart failure (CHF). Already available in Europe, where it has enjoyed moderate use in CHF and stable angina patients, ivabradine's sound clinical...

2013-08-12 20:22:01

THOUSAND OAKS, Calif. and SURESNES, France, Aug. 12, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Servier today announced the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product collaboration agreement announced on July 8, 2013, completing the transaction. Under the terms of the agreement, Amgen has obtained commercial rights in the U.S. to Servier's novel oral drug, approved in the EU as...

2013-07-09 08:29:41

Amgen Obtains US Rights to Novel EU-Approved Cardiovascular Therapy; Servier Receives Option for Omecamtiv Mecarbil in Europe THOUSAND OAKS, Calif., and SURESNES, France, July 9, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Servier today announced a new collaboration agreement leveraging each company's commitment to cardiovascular disease. Under the terms of the agreement, Amgen has obtained commercial rights in the U.S. to Servier's novel oral drug, approved in the EU as...

2011-08-29 14:05:42

As guest speaker at the European Society of Cardiology's Congress currently under way in Paris, Dr. Jean-Claude Tardif, Director of the Montreal Heart Institute's Research Centre and professor of medicine at the Université de Montréal, today presented the results of an analysis demonstrating that ivabradine, a medication used to reduce heart rate, also reduces heart volume (left ventricle) among patients with cardiac insufficiency. In 2010, the findings of the...

2011-07-28 17:44:30

The findings of a Montreal Heart Institute (MHI) study published in the scientific journal Cardiology suggest that ivabradine, a heart rate reduction medication, is also effective in reducing the risk of diastolic heart failure (left ventricular insufficiency) and cardiac fibrosis. The benefits of slower heart rate on mortality and morbidity associated with cardiovascular disease no longer need to be demonstrated. In this study, titled "Heart Rate Reduction by Ivabradine Reduces Diastolic...

603d046199c34a371d665a3f55b5088b1
2010-08-30 13:18:17

Trial results published Monday show that a pill for chest pains could help save the lives of thousands of heart failure patients and dramatically reduce hospital admissions. Professor Martin Cowie, who led the study, told AFP news that the drug could help prevent up to 10,000 deaths every year in the U.K.  Ivabradine, which is also known under the brand name Procoralan, is already available in the UK for angina. The study involved over 6,500 patients that all had chronic heart failure...